New hope for easing debilitating symptoms in rare blood cancers
NCT ID NCT04644211
Summary
This study is testing whether the drug ruxolitinib can reduce the often severe symptoms experienced by people with low-risk essential thrombocythemia (ET) or polycythemia vera (PV). About 60 participants with significant symptom burdens will take the drug for at least 6 months to see if it improves their quality of life. The main goal is to see if the treatment can cut patients' total symptom scores in half.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth-Israel Deaconess Medical Center
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General North Shore Cancer Center
RECRUITINGDanvers, Massachusetts, 01923, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.